Neovasc Inc. is a specialized medical technology enterprise focused on the development, production, and worldwide distribution of products for the cardiac health sector, with a significant presence across Europe and other international markets. The company's key innovations feature the Tiara system, an advanced transcatheter technology for managing mitral valve disease, and the Neovasc Reducer, which offers a therapeutic option for patients suffering from refractory angina. Founded in 2000, the organization initially operated as Medical Ventures Corp. before adopting the name Neovasc Inc. in July 2008.